LY-367,265

LY-367,265 is a drug that acts as a serotonin and norepinephrine reuptake inhibitor, and 5-HT1A receptor agonist. It was developed by Eli Lilly for the treatment of depression and anxiety disorders, but was discontinued in the early stages of clinical trials due to poor bioavailability.

Pharmacology

LY-367,265 is a serotonin-norepinephrine reuptake inhibitor (SNRI) and a 5-HT1A receptor agonist. It works by inhibiting the reuptake of serotonin and norepinephrine, two neurotransmitters in the brain that are involved in mood regulation. By blocking their reuptake, LY-367,265 increases the levels of these neurotransmitters in the brain, which can help to alleviate symptoms of depression and anxiety.

In addition to its SNRI activity, LY-367,265 also acts as an agonist at the 5-HT1A receptor. This receptor is involved in a variety of functions in the brain, including the regulation of mood, anxiety, and sleep. By activating this receptor, LY-367,265 may provide additional benefits in the treatment of depression and anxiety disorders.

Clinical Trials

LY-367,265 was developed by Eli Lilly and entered into clinical trials for the treatment of depression and anxiety disorders. However, the drug was discontinued in the early stages of development due to poor bioavailability. Bioavailability refers to the extent and rate at which a drug is absorbed and becomes available at the site of drug action. Despite its promising pharmacological profile, LY-367,265 was not able to be effectively absorbed and utilized by the body, limiting its therapeutic potential.

See Also

• Serotonin-norepinephrine reuptake inhibitor
• 5-HT1A receptor
• Eli Lilly and Company
• Depression
• Anxiety disorders

References

<references />

This article is a stub related to pharmacology. You can help WikiMD by expanding it!